These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27039149)

  • 41. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
    Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
    J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
    Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
    J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
    Espelin CW; Leonard SC; Geretti E; Wickham TJ; Hendriks BS
    Cancer Res; 2016 Mar; 76(6):1517-27. PubMed ID: 26759238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
    Jiang W; Lionberger R; Yu LX
    Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
    Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
    Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin
    Yokoe I; Omata D; Unga J; Suzuki R; Maruyama K; Okamoto Y; Osaki T
    Drug Deliv; 2021 Dec; 28(1):530-541. PubMed ID: 33685314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
    Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
    Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
    Arima H; Hagiwara Y; Hirayama F; Uekama K
    J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
    Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
    AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
    Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
    Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
    Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
    J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
    Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
    J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.